Levofloxacin Oral Solution Suppliers & Bulk Manufacturers

Available Forms: Oral Solution

Available Strengths: 25 mg/mL, 50 mg/mL, 100 mg/5 mL

Reference Brands: Levaquin (USA), Tavanic (EU/LATAM), Levox (India)

Category: Antibiotics

Levofloxacin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Indication and Usage: Which are effective against a number of Gram – positive & Gram negative bacteria & specifically against the organisms that cause atypical pneumonia. Levofloxacin Oral Solution is available in Oral Solution and strengths such as 25 mg/mL, 50 mg/mL, 100 mg/5 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Levofloxacin Oral Solution is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Levofloxacin Oral Solution can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Levofloxacin is an FDA-approved broad-spectrum fluoroquinolone antibiotic indicated for the treatment of a wide range of bacterial infections. It is used for both community-acquired and nosocomial pneumonia, acute bacterial rhinosinusitis, acute bacterial exacerbations of chronic bronchitis, acute bacterial prostatitis, acute pyelonephritis, urinary tract infections, and skin or skin structure infections. Additionally, levofloxacin is indicated for prophylaxis and treatment of plague caused by Yersinia pestis and to reduce disease progression in inhalational anthrax.

Levofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair, effectively preventing bacterial growth and proliferation. While highly effective, it carries potential adverse effects, including pseudomembranous colitis, hepatotoxicity, and QT interval prolongation. Therefore, proper patient education and monitoring are essential to ensure safety, including prompt discontinuation if serious symptoms arise.

This comprehensive activity highlights levofloxacin’s clinical applications, FDA box warnings, monitoring strategies, and key drug interactions. By understanding its therapeutic profile and safety considerations, healthcare professionals can effectively integrate levofloxacin into clinical practice to manage diverse bacterial infections while minimizing risks, ultimately supporting improved patient outcomes.